Inclusion Criteria:

• Participants aged between 19 and 50 years.
• Eligible for treatment with semaglutide, defined as either:
• Initial body mass index (BMI) of 30 kg/m2 or higher; or
• Initial BMI of 27 kg/m2 to less than 30 kg/m2 with at least one weight-related comorbidity, such as dysglycemia, hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease.
• Mild or greater food addiction tendency, defined as a Yale Food Addiction Scale (YFAS) score of 3 or higher.
• Able to understand the study tasks and provide appropriate responses.

Exclusion Criteria:

• Use of medications that may affect body weight or dopaminergic medications within the past 2 months.
• Known hypersensitivity to semaglutide.
• Pregnant, breastfeeding, or planning to become pregnant.
• Severe renal impairment, hepatic impairment, heart failure, acute pancreatitis, or thyroid disease.
• Any medical condition, disease, or medical history that, in the investigator's judgment, would make it difficult for the participant to complete the study or would interfere with interpretation of the study results.
• Allergy to ingredients in chocolate milk, including milk or soy, or to ingredients that may be present through cross-contamination, including egg, buckwheat, peanut, wheat, peach, tomato, walnut, pork, or beef.
• Participants with both no self-reported preference for chocolate milk and a chocolate milk preference score of less than 5 on a 10-point visual analog scale (VAS).